New treatment stops progression of prostate cancer: report

by



[ad_1]

A drug already proven effective in the fight against breast cancer could help men win the war against prostate cancer, according to a landmark study in London.

The drug, called talazoparib, is taken as a daily pill and is already used successfully by breast cancer patients, according to the Sunday Times.

The report, citing research from the Institute of Cancer Research in London and the Royal Marsden NHS Foundation Trust, said phase two trials of the drug halted the progression of advanced prostate cancer by 5.6 months on average. – double the time possible with existing treatments. .

“Talazoparib is now one of a handful of precision drugs that have been shown to be safe and effective in controlling advanced prostate cancer,” said Matthew Hobbs, director of research at Prostate Cancer UK. “We need to move forward as quickly as possible in this area. “

A male patient sees a doctor about prostate cancer.
Talazoparib has also been used in patients with breast cancer.
Alamy Stock Photo
Talazoparib, sold under the brand name Talzenna, is an orally available poly ADP ribose polymerase (PARP) inhibitor developed by Pfizer for the treatment of advanced breast cancer with germline BRCA mutations.
Talazoparib is particularly effective for patients with prostate cancer with a mutated BRCA gene.
Pfizer

The treatment has been shown to be particularly effective for men with a mutated BRCA gene who are genetically predisposed to prostate cancer – similar to the mutation carried by Angelina Jolie, which increased her risk of ovarian and breast cancer. breast.

The Lancet Oncology Journal published the results of the study this month.

[ad_2]

Source link